Helen Schiltz

Helen Schiltz has a wealth of experience in corporate development, research and development, product development, and therapeutics development. Helen began their career in 1985 as an Assistant Professor at South China Normal University. In 1995, they became Manager of Research and Development at Digene, where they led the Novel Technology Assessment program and identified and developed multiplex assay platforms. From 2000 to 2004, they served as Associate Director of Product Development at Metrigenix and then as Program Officer of Therapeutics Development at the National Institutes of Health. Since 2020, they have been VP of Corporate Development at both OncoC4, Inc. and ONCOIMMUNE, INC., and Senior Director of Research and Development at Sabin Vaccine Institute.

Helen Schiltz obtained their Bachelor of Science in Biology from South China Normal University between 1979 and 1983. Helen then went on to earn their Master of Science in Plant Physiology from Sun Yat-sen University from 1983 to 1985. Finally, they completed their PhD in Biochemistry from Louisiana State University between 1989 and 1995.